<code id='AA3B90A0B3'></code><style id='AA3B90A0B3'></style>
    • <acronym id='AA3B90A0B3'></acronym>
      <center id='AA3B90A0B3'><center id='AA3B90A0B3'><tfoot id='AA3B90A0B3'></tfoot></center><abbr id='AA3B90A0B3'><dir id='AA3B90A0B3'><tfoot id='AA3B90A0B3'></tfoot><noframes id='AA3B90A0B3'>

    • <optgroup id='AA3B90A0B3'><strike id='AA3B90A0B3'><sup id='AA3B90A0B3'></sup></strike><code id='AA3B90A0B3'></code></optgroup>
        1. <b id='AA3B90A0B3'><label id='AA3B90A0B3'><select id='AA3B90A0B3'><dt id='AA3B90A0B3'><span id='AA3B90A0B3'></span></dt></select></label></b><u id='AA3B90A0B3'></u>
          <i id='AA3B90A0B3'><strike id='AA3B90A0B3'><tt id='AA3B90A0B3'><pre id='AA3B90A0B3'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:hotspot    Page View:29
          Fetal ultrasound
          Adobe

          The artificial womb, a device aiming to save infants born way too soon, is inching closer to being tested in humans.

          The technology is close enough to reality that the Food and Drug Administration has decided to convene a two-day panel starting Tuesday to discuss how to best evaluate safety and effectiveness, as well as the ethical quandaries in running clinical trials. The second day will be closed to the public to shield trade secrets.

          advertisement

          Several research teams are racing to build artificial placentas that replicate the uterine environment and give the very prematurely born a better shot at survival. A team at the Children’s Hospital of Philadelphia, led by Alan Flake, is the closest to human trials — their device is a bag filled with sterile fluid, which contains the fetus and is connected to tubes providing oxygen and nutrition.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          How to save PrEP access — and even expand it
          How to save PrEP access — and even expand it

          UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

          read more
          Readout Newsletter: The latest on Moderna, Apellis, and Merck
          Readout Newsletter: The latest on Moderna, Apellis, and Merck

          JakubPorzycki/NurPhotoviaAPWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetou

          read more
          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more

          Violet CEO on training clinicians to promote more inclusive care

          GaurangChoksiisthefounderandCEOofViolet,ahealthequityplatform.CourtesyGaurangChoksiPHOENIX,Ariz.—Gau